JP2023505222A - 免疫増強および腫瘍処置のための方法 - Google Patents

免疫増強および腫瘍処置のための方法 Download PDF

Info

Publication number
JP2023505222A
JP2023505222A JP2022533442A JP2022533442A JP2023505222A JP 2023505222 A JP2023505222 A JP 2023505222A JP 2022533442 A JP2022533442 A JP 2022533442A JP 2022533442 A JP2022533442 A JP 2022533442A JP 2023505222 A JP2023505222 A JP 2023505222A
Authority
JP
Japan
Prior art keywords
tumor
lesion
cells
cancer
fiber length
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022533442A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505222A5 (https=
Inventor
ミゲル ガルシア－グスマン
ジェリー フォン
エイミー ソーン
ミシェル シュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rakuten Medical Inc
Original Assignee
Rakuten Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rakuten Medical Inc filed Critical Rakuten Medical Inc
Publication of JP2023505222A publication Critical patent/JP2023505222A/ja
Publication of JP2023505222A5 publication Critical patent/JP2023505222A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022533442A 2019-12-06 2020-12-04 免疫増強および腫瘍処置のための方法 Pending JP2023505222A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945053P 2019-12-06 2019-12-06
US62/945,053 2019-12-06
PCT/US2020/063444 WO2021113734A1 (en) 2019-12-06 2020-12-04 Methods for enhancing immunity and tumor treatment

Publications (2)

Publication Number Publication Date
JP2023505222A true JP2023505222A (ja) 2023-02-08
JP2023505222A5 JP2023505222A5 (https=) 2023-12-12

Family

ID=73856374

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022533442A Pending JP2023505222A (ja) 2019-12-06 2020-12-04 免疫増強および腫瘍処置のための方法

Country Status (6)

Country Link
US (1) US20230028062A1 (https=)
EP (1) EP4069300A1 (https=)
JP (1) JP2023505222A (https=)
CN (1) CN115052631A (https=)
TW (1) TW202133886A (https=)
WO (1) WO2021113734A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024505556A (ja) * 2021-02-02 2024-02-06 ラクテン・メディカル，インコーポレイテッド がん、腫瘍および腫瘍細胞の局所および全身処置のための方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2889904T3 (es) 2015-08-18 2022-01-14 Rakuten Medical Inc Conjugados de colorante de ftalocianina y su almacenamiento
AU2023221861A1 (en) * 2022-02-18 2024-09-05 Rakuten Medical, Inc. Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
CN115364238B (zh) * 2022-08-16 2024-02-02 山东大学 一种阿特珠单抗-mmad结合物及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018528268A (ja) * 2015-08-18 2018-09-27 アスピリアン セラピューティクス インコーポレイテッド 光免疫療法のための組成物、組み合わせおよび関連方法
JP2018528267A (ja) * 2015-08-18 2018-09-27 アスピリアン セラピューティクス インコーポレイテッド フタロシアニン色素コンジュゲートおよびその保存法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
CA3070469C (en) 2016-10-25 2022-06-21 Rakuten Medical, Inc. Light diffusing devices for use in photoimmunotherapy
US10416366B2 (en) 2016-10-25 2019-09-17 Rakuten Medical, Inc. Light diffusing devices for use in photoimmunotherapy
JP2020508323A (ja) * 2017-02-23 2020-03-19 ラクテン メディカル インコーポレイテッド 光免疫療法のための治療用組成物および関連する方法
CN115943306A (zh) * 2019-03-29 2023-04-07 乐天医药生技股份有限公司 用于光免疫疗法的方法和相关生物标志物
CN114423453A (zh) * 2019-07-30 2022-04-29 乐天医药生技股份有限公司 使用偶联的抗cd25酞菁和抗pd1的基于光化学的癌症疗法近红外(nir)光免疫疗法(pit)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018528268A (ja) * 2015-08-18 2018-09-27 アスピリアン セラピューティクス インコーポレイテッド 光免疫療法のための組成物、組み合わせおよび関連方法
JP2018528267A (ja) * 2015-08-18 2018-09-27 アスピリアン セラピューティクス インコーポレイテッド フタロシアニン色素コンジュゲートおよびその保存法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
2019 CONFERENCE ON LASERS AND ELECTRO-OPTICS (CLEO), JPN6024051720, May 2019 (2019-05-01), pages 1 - 2, ISSN: 0005694365 *
ACC. CHEM. RES., vol. vol.52, issue 8, JPN6024051721, July 2019 (2019-07-01), pages 2332 - 2339, ISSN: 0005694364 *
CANCER IMMUNOL. RES., vol. vol.7, issue 3, JPN6024051719, March 2019 (2019-03-01), pages 401 - 413, ISSN: 0005694366 *
ONCOTARGET, vol. 8, no. 5, JPN6024051722, 2017, pages 8807 - 8817, ISSN: 0005694363 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024505556A (ja) * 2021-02-02 2024-02-06 ラクテン・メディカル，インコーポレイテッド がん、腫瘍および腫瘍細胞の局所および全身処置のための方法

Also Published As

Publication number Publication date
CN115052631A (zh) 2022-09-13
US20230028062A1 (en) 2023-01-26
WO2021113734A1 (en) 2021-06-10
EP4069300A1 (en) 2022-10-12
TW202133886A (zh) 2021-09-16

Similar Documents

Publication Publication Date Title
KR102595561B1 (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
US20220324965A1 (en) Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
JP2023505222A (ja) 免疫増強および腫瘍処置のための方法
BR112015023910B1 (pt) terapia envolvendo anticorpos contra claudin 18.2 para tratamento de câncer
JP7460608B2 (ja) 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法
JP2021522298A (ja) 癌治療のためのＰＤ−１／ＰＤ−Ｌ１、ＴＧＦβおよびＤＮＡ−ＰＫの同時阻害
CN110494161A (zh) 用于治疗癌症的抗pd-l1抗体和dna-pk抑制剂的组合
JP2022515188A (ja) がん治療のための組成物および方法
JP2022543765A (ja) 抗ｃｄ２５抗体－フタロシアニン色素コンジュゲートおよび抗ｐｄ１抗体を使用したがんの処置のための近赤外（ｎｉｒ）光免疫療法（ｐｉｔ）
JP2025501885A (ja) 抗ｔｒｏｐ－２抗体薬物複合体と他の治療薬との併用
CN112969718A (zh) Il-15蛋白复合物联合pd-l1抗体用于治疗肿瘤疾病的用途
KR20210066837A (ko) 암 치료를 위한 pd-1 안타고니스트, atr 억제제 및 백금화제의 조합
JP2018016619A (ja) Ａｌｌｅｒｇｉｎ−１アンタゴニストによるがん免疫増強剤
US20220296712A1 (en) Methods for treatment using phthalocyanine dye-targeting molecule conjugates
KR20240099362A (ko) 혈액암에 대한 lag-3 길항제 요법
CN121443320A (zh) 含有抗ceacam5抗体-药物缀合物、抗pd1/pd-l1抗体和抗ctla4抗体的抗肿瘤组合
JP2025542297A (ja) 肺癌の組み合わせ療法
WO2020049534A1 (en) Sting agonist and combination therapy thereof for the treatment of cancer
HK40051088A (en) Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases
EA053135B1 (ru) Лечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство
EA048671B1 (ru) Конъюгаты антител к тканевому фактору с лекарственными средствами и их применение при лечении рака
EA049388B1 (ru) Способы лечения базально-клеточной карциномы путем введения антитела или его антигенсвязывающего фрагмента, специфически связывающихся с pd-1
BR112017027026B1 (pt) Usos de um antagonista de pd-l1 e de um inibidor de vegfr, medicamentos e kits compreendendo os mesmos

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260323